New hope for an unusual form of heart failure
Long summary: Up to 15% of people with a stiff, thickened heart (known as heart failure with preserved ejection fraction) may have cardiac amyloidosis. Advances in cardiac imaging have improved the ability to diagnose the condition, which is caused by clumps of an abnormal protein (amyloid) deposited in heart tissue. Most cases are known as ATTR amyloidosis, which has an inherited form and a non-inherited form. Tafamidis (Vyndaqel), the first drug to treat ATTR cardiac amyloidosis, was approved by the FDA last year.
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Already a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
